• JUser: :_load: Unable to load user with ID: 44
Category: Marketing

Bangalore, May 20, 2014 -

Wipro Ltd. (NYSE:WIT), a leading global Information Technology, Consulting and Outsourcing company today announced a strategic partnership with Takeda Pharmaceutical Company Ltd., the largest pharmaceutical company in Japan and one of the global leaders of the industry.

This strategic partnership will build advanced value in Takeda's operations by consolidating IT platforms across the organization. As a strategic partner, Wipro will build and maintain an “as-a-service” global platform for Takeda that will drive synergies across its global entities through standardization of IT architecture. Wipro will be primary provider of IT Infrastructure management services covering Takeda’s entities across the world, touching 30,000 users in 16 different languages, operating out of data centers in Asia, Europe and America.

Speaking on the engagement, Sangita Singh, Chief Executive - Healthcare and Life Science Business Unit at Wipro said, “We are thrilled to partner with Takeda in its business transformation journey. Wipro is leveraging its 

experience in enabling global pharma companies to achieve a leaner & standardized IT workplace and implement newer business models that put patient at the core. We look forward to collaboratively partnering with the Takeda team in enabling this unique platform across its global operations.”

“Wipro will deliver the “as-a-service” on demand model, which is redefining the way organizations purchase technology. With our global delivery capabilities, Wipro will drive Takeda’s IT infrastructure, consolidating and optimizing resources across the organization,” added G K Prasanna, Chief Executive - Global Infrastructure Services & Product Engineering Services. 

Category: Marketing

MUMBAI, APRIL 25, 2014 :

Drugmaker Lupin Ltd has entered into a joint venture agreement with Japanese pharmaceuticals company Yoshindo Inc to create a new entity, YL Biologics (YLB).

YLB will be jointly managed by both partners and will be responsible for conducting clinical development of certain biosimilars including regulatory filings and obtaining marketing authorisations in Japan, Lupin said.

The new entity YLB will in-license monoclonal antibodies (mAbs) from Lupin and also partner with other companies across the globe for the Japanese market which already has a clear cut regulatory regime in place for the development and commercialisation of biologicals.

Lupin’s Etanercept biosimilar, developed by its biotechnology research group in Pune will be the first product to be licensed for clinical development to YLB. Etanercept is a biopharmaceutical product approved globally for treating autoimmune diseases such as rheumatoid arthritis, psoriasis and ankylosing spondylitis. Originally sold as Enbrel, the drug is marketed in Japan by Takeda Pharmaceutical and has a sales of $496 million, up to March 2013.

The Japanese biological market is valued at about $ 12 billion and growing at three per cent annually. And monoclonal antibodies account for about $3.5 billion of the overall Japanese biological sales, growing at 5 per cent.

Lupin will be entitled to milestone based licensing income in addition to commercial supplies of the drug substance, Lupin sid. Both Lupin and Yoshindo will then market the product under their own brand names by leveraging their respective sales networks. Business Line

Category: Marketing

Paris, March 12, 2014: Specifically, the collaboration will look at anti-inflammatory small molecules that have the potential to treat a wide range of immune-mediated diseases in areas such as gastroenterology and arthritis.

The terms of the agreement see Sanofi and Belgium-based UCB sharing costs and profits on a 50/50 basis. UCB will be entitled to initial pre-clinical and clinical development milestone payments upfront from Sanofi, potentially exceeding €100 million ($139 million).

There is already a large and competitive market for these types of medicines - notably in arthritis, which sees some of the biggest-selling treatments in the world catering for the disease.

But the two firms will hope that they can still edge their way into the field and gain some share.

UCB already has its arthritis treatment Cimzia (certolizumab pegol) pulling in healthy revenue, which analysts believe should bring in sales of around €1.5 billion at its peak (with additional licences).

Sanofi on the other hand has predominately focussed on heart drugs, multiple sclerosis, cancer medicines and treatments for rare diseases, especially since its purchase of Genzyme in 2011.

For Sanofi this partnership will enable it to use the established R&D pathways of UCB to develop these auto-immune medicines, whilst exploiting its own global clout and financial backing to help sell them - should they gain approval.

Ismail Kola, president of UCB’s NewMedicines [sic] unit, said: “We partner Sanofi’s significant expertise, strong capabilities and resources with UCB’s cutting-edge research skills and breakthrough innovations.

“Together we can maximise the opportunity to treat diseases currently treated by biologic agents with small molecules and thus benefit millions of people suffering from severe diseases.”

UCB NewMedicines, the research arm of UCB, said that a ‘dedicated team of scientists’ will be formed under the leadership of Sanofi and itself, and will join forces in a discovery and development based collaboration to characterise and identify new potential therapies.

“Immune-mediated diseases affect individuals, families, and communities and impact the economies of countries and nations, making this poorly understood category of diseases a significant public health burden,” said Dr Elias Zerhouni, president of global R&D at Sanofi.

“Joining efforts with UCB, we will address a scientific challenge in immunology, and increase the chances of accelerating the discovery and development of future therapies.”

New deals

UCB has been increasingly looking towards partnerships of recent years, and in January launched a new online campaign to allow the public to help them develop new medicines.

Sanofi too has been looking outside of its walls for deals, with many in recent months revolving around syndicates on rare diseases.

Deals between one big pharma company and a second a small-to-mid range firm seem to be a growing trend within the industry. Big pharma is finding it more difficult to create the next innovation in-house. It has the money and the reach, but not always the innovation in its research centres.

The opposite is generally true for smaller firms like UCB who have the ideas, but not the money to always progress medicines on its own.

Agreements such as the one announced today are the result of these dilemmas, and are indicative of the industry’s desire to de-risk. Pharma File

Category: Marketing

New Delhi, March 12, 2014:
The drug maker will source active pharmaceutical ingredients, or the raw material used to make finished medicines, from these plants.

A senior company official said Ranbaxy already has some ingredient manufacturing sites in place and would source the ingredients from these plants.

According to reports, the company is also in talks with two companies for sourcing ingredients for a generic version of AstraZeneca Plc's heartburn pill Nexium.

However, a company spokesperson refused to comment on this particular move.

Category: Marketing

The drugs had been suspended by the Health Ministry earlier this year. But following a safety review of these medicines by an expert committee, the Drugs Technical Advisory Board (DTAB) has now recommended that they be permitted for use, as they are given in smaller dosages and over few days, respectively.

However, the Board did not recommend revoking the suspension on anti-depressant Deanxit, whose manufacture and sale had also been discontinued this year.

In fact, Deanxit, along with Analgin and diabetes drug pioglitazone had been suspended in June over safety concerns. But the suspension of pioglitazone has already been revoked, and the drug is back in the market with warning – labels and riders of restricted use. The drug had been suspended on possible links to urinary bladder cancer.

Dextropropoxyphene should be allowed for limited use for cancer patients, and it needs to be labelled “for use in cancer patients for pain only”, the DTAB recommended. Experts observed that dextropropoxyphene was the only opioid drug available for treatment in cancer-related pain. The drug was banned in India after regulators in the US and Europe recommended against its use, as its risks outweighed benefits – there were concerns of toxicity to the heart.

During the safety evaluation, the expert committee found that the heart impact was with higher dosages of 600 mg, while Indian patients were prescribed 300 mg per day.

The committee streamlined the drugs usage, suggesting that dosages not exceed 300 mg per day, and that the drug be put under post-marketing surveillance, even a controlled clinical trial to evaluate its safety in Indian subjects. Companies were also asked to submit safety data on the Indian population for six-month periods.

As for Analgin (metamizole), it should be allowed for severe pain or pain due to tumour, and for bringing down body temperature when other medicines in the category fail, the DTAB said. The drug is given over few days and there were no “adequate reports” of side-effects linked to the drug, it added. Concerns over Analgin are linked to its impact on an individual’s white blood cells that further affected the body’s immunity.

Ban continues

The suspension of Deanxit (Flupenthixol with melitracen) remained unchanged as the expert committee found the “rationality and essentiality” of continued marketing of this combination drug questionable.

Melitracen was reportedly not efficacious as a single agent in depression and Flupenthixol use was associated with potentially serious neurologic side effects, the committee said.

In fact, it pointed out that since Flupenthixol was an anti-psychotic drug and Melitracen an anti-depressant drug, their combination could lead to increased impact on the nervous system. Though Deanxit was approved for local use in October 1998, the drug is not marketed in the country of its origin, Denmark, besides countries such as the US, Britain, Canada, European Union and Japan. Business line

Email address:

Prev Next
"ACCURA" MODEL ACT -III High Speed Double Rotary Tablet Presses
Pharmaceutical Labeling Equipment
The Power Times.in
The SME Times
 The Pharma Times News Portal
The Hotel Times
  • 1
  • 2
Prev Next
Omron Blood Pressure Monitor, HEM-7113
Automatic Capsule Filling Machine (PF-150)
Gelusil liquid antacid - Pfizer’s
The Varilux 3.0 range lenses - Essilor
Blossom Kochhar Aroma Magic Anti Pigmentation Serum
 The Property Times